Biomea Fusion, Inc.
About Biomea Fusion, Inc.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $1.2B
- Net income
- -$61.8M
- Total assets
- $58.6M
- Market cap
- $91.8M
- Operating margin
- -4494.7%
- Net margin
- -3326.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.9M
- Operating expenses
- $83.5M
- Operating income
- -$83.5M
- Income tax
- $0
- Net income
- -$61.8M
- EPS (basic)
- $-1.18
- EPS (diluted)
- $-1.18
Balance sheet
- Total assets
- $58.6M
- Current assets
- $58.0M
- Total liabilities
- $29.0M
- Current liabilities
- $11.1M
- Shareholders’ equity
- $29.6M
Cash flow
- Operating cash flow
- -$70.4M
- Investing cash flow
- $2.5M
- Financing cash flow
- $67.9M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $91.8M
- EPS (diluted)
- $-1.18
- Shares outstanding
- 79.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 16, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $61.8M in FY2022.
- Trading 60% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Biomea Fusion, Inc..
Write a review
News about Biomea Fusion, Inc.
News & sentiment via Polygon.io
